Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05351580 · ClinicalTrials.gov registry record
DiSCERN: Advanced PD Therapy Candidacy and Evaluation System
A clinical trial, sponsored by Great Lakes NeuroTechnologies.
- Completed
- Registry status
- 26
- Enrollment target
NCT05351580: Completed study, sponsored by Great Lakes NeuroTechnologies.
NCT05351580 is a clinical trial that has completed, run by Great Lakes NeuroTechnologies. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05351580 has completed, sponsored by Great Lakes NeuroTechnologies.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
To collect data to develop models that identify when patients with advanced Parkinson's disease (PD) are not responding well to their current therapy and may be ready to consider advanced therapy and when patients receiving advanced therapy are not responding well and need a therapy adjustment.
Primary Outcome
Symptom severities measured by smart watch
Interventions
- DEVICE DiSCERN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2024-06-30 |
What the finished NCT05351580 record still lists
NCT05351580 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which DiSCERN is the first listed.
NCT05351580 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05351580 about?
NCT05351580 is a clinical study titled "DiSCERN: Advanced PD Therapy Candidacy and Evaluation System". To collect data to develop models that identify when patients with advanced Parkinson's disease (PD) are not responding well to their current therapy and may be ready to consider advanced therapy and when patients receiving advanced therapy are not responding well and need a therapy adjustment.
What is the current status of trial NCT05351580?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2022-07-21. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT05351580?
The interventions under investigation include: DiSCERN (DEVICE).
Who is sponsoring clinical trial NCT05351580?
This trial is sponsored by Great Lakes NeuroTechnologies, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI